FULC
Price
$6.82
Change
-$0.08 (-1.16%)
Updated
Jun 11, 04:59 PM (EDT)
Capitalization
372.46M
56 days until earnings call
OMER
Price
$3.61
Change
-$0.27 (-6.96%)
Updated
Jun 11, 04:59 PM (EDT)
Capitalization
227.34M
56 days until earnings call
Interact to see
Advertisement

FULC vs OMER

Header iconFULC vs OMER Comparison
Open Charts FULC vs OMERBanner chart's image
Fulcrum Therapeutics
Price$6.82
Change-$0.08 (-1.16%)
Volume$3.59K
Capitalization372.46M
Omeros
Price$3.61
Change-$0.27 (-6.96%)
Volume$11.26K
Capitalization227.34M
FULC vs OMER Comparison Chart
Loading...
FULC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OMER
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
FULC vs. OMER commentary
Jun 12, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FULC is a Hold and OMER is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 12, 2025
Stock price -- (FULC: $6.90 vs. OMER: $3.88)
Brand notoriety: FULC and OMER are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FULC: 65% vs. OMER: 121%
Market capitalization -- FULC: $372.46M vs. OMER: $227.34M
FULC [@Biotechnology] is valued at $372.46M. OMER’s [@Biotechnology] market capitalization is $227.34M. The market cap for tickers in the [@Biotechnology] industry ranges from $333.72B to $0. The average market capitalization across the [@Biotechnology] industry is $2.4B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FULC’s FA Score shows that 1 FA rating(s) are green whileOMER’s FA Score has 1 green FA rating(s).

  • FULC’s FA Score: 1 green, 4 red.
  • OMER’s FA Score: 1 green, 4 red.
According to our system of comparison, both FULC and OMER are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FULC’s TA Score shows that 3 TA indicator(s) are bullish while OMER’s TA Score has 4 bullish TA indicator(s).

  • FULC’s TA Score: 3 bullish, 4 bearish.
  • OMER’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, both FULC and OMER are a bad buy in the short-term.

Price Growth

FULC (@Biotechnology) experienced а -1.92% price change this week, while OMER (@Biotechnology) price change was +23.57% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.36%. For the same industry, the average monthly price growth was +14.54%, and the average quarterly price growth was +6.60%.

Reported Earning Dates

FULC is expected to report earnings on Aug 06, 2025.

OMER is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+5.36% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
FULC($372M) has a higher market cap than OMER($227M). FULC YTD gains are higher at: 46.809 vs. OMER (-60.729). FULC has higher annual earnings (EBITDA): -8.94M vs. OMER (-155.96M). FULC has more cash in the bank: 227M vs. OMER (123M). FULC has less debt than OMER: FULC (8.11M) vs OMER (209M). FULC has higher revenues than OMER: FULC (80M) vs OMER (0).
FULCOMERFULC / OMER
Capitalization372M227M164%
EBITDA-8.94M-155.96M6%
Gain YTD46.809-60.729-77%
P/E RatioN/AN/A-
Revenue80M0-
Total Cash227M123M185%
Total Debt8.11M209M4%
FUNDAMENTALS RATINGS
FULC vs OMER: Fundamental Ratings
FULC
OMER
OUTLOOK RATING
1..100
213
VALUATION
overvalued / fair valued / undervalued
1..100
26
Undervalued
44
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
8811
PRICE GROWTH RATING
1..100
3595
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FULC's Valuation (26) in the null industry is in the same range as OMER (44) in the Biotechnology industry. This means that FULC’s stock grew similarly to OMER’s over the last 12 months.

FULC's Profit vs Risk Rating (100) in the null industry is in the same range as OMER (100) in the Biotechnology industry. This means that FULC’s stock grew similarly to OMER’s over the last 12 months.

OMER's SMR Rating (11) in the Biotechnology industry is significantly better than the same rating for FULC (88) in the null industry. This means that OMER’s stock grew significantly faster than FULC’s over the last 12 months.

FULC's Price Growth Rating (35) in the null industry is somewhat better than the same rating for OMER (95) in the Biotechnology industry. This means that FULC’s stock grew somewhat faster than OMER’s over the last 12 months.

FULC's P/E Growth Rating (100) in the null industry is in the same range as OMER (100) in the Biotechnology industry. This means that FULC’s stock grew similarly to OMER’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
FULCOMER
RSI
ODDS (%)
Bearish Trend 2 days ago
75%
Bullish Trend 2 days ago
76%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
80%
Momentum
ODDS (%)
N/A
Bullish Trend 2 days ago
72%
MACD
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
77%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 6 days ago
86%
Bullish Trend 8 days ago
82%
Declines
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 10 days ago
88%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
73%
Aroon
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
FULC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OMER
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FTAWX13.78N/A
N/A
Fidelity Advisor Asset Manager 20% A
SWANX23.63N/A
N/A
Schwab Core Equity
DURSX14.15N/A
N/A
DWS ESG International Core Eq S
MELSX16.13N/A
N/A
Morgan Stanley Inst EMkts Ldrs R6
HGASX28.08N/A
N/A
Hennessy Gas Utility Institutional

FULC and

Correlation & Price change

A.I.dvisor indicates that over the last year, FULC has been loosely correlated with SLS. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if FULC jumps, then SLS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FULC
1D Price
Change %
FULC100%
-3.09%
SLS - FULC
48%
Loosely correlated
-1.91%
ANNX - FULC
40%
Loosely correlated
+1.93%
VRDN - FULC
39%
Loosely correlated
+3.77%
MLTX - FULC
34%
Loosely correlated
-1.18%
ITOS - FULC
34%
Loosely correlated
-0.10%
More

OMER and

Correlation & Price change

A.I.dvisor indicates that over the last year, OMER has been loosely correlated with VCYT. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if OMER jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OMER
1D Price
Change %
OMER100%
+2.92%
VCYT - OMER
40%
Loosely correlated
+0.11%
INM - OMER
36%
Loosely correlated
-2.81%
MDXG - OMER
33%
Loosely correlated
+1.24%
FULC - OMER
31%
Poorly correlated
-3.09%
KYMR - OMER
31%
Poorly correlated
+3.05%
More